Skip to content
Mali

Mali: study finds malaria antibody interferes with R21 vaccine in infants

Close-up of a mosquito on human skin
A mosquito on human skin (file)

Madar (Bamako) - A study in infants in Mali, presented on Thursday, 19 November 2026, found that the monoclonal antibody L9LS was 78% effective against the malaria parasite compared with a placebo, but weakened the immune response to the R21 vaccine, according to the health news site STAT.

According to the same source, the study enrolled infants aged one to twelve months, who received either a placebo or L9LS, followed by doses of the R21 vaccine. Protection covered the six-month transmission season.

The results, presented as an abstract at the annual meeting of the American Society of Tropical Medicine and Hygiene, showed a 20% to 30% drop in the antibody levels generated by the vaccine in infants who had first received L9LS.

Researchers believe the cause is that the vaccine and the antibody target the same protein on the parasite, so the antibody binds to the vaccine and limits the full immune response it is meant to trigger. It is not yet clear what the lower response means for the vaccine's real-world protection.

"A monoclonal antibody, with only one shot, provides an efficacy over six months, and those six months correspond to the season of malaria in Sahelian regions," said Malian researcher Kassoum Kayentao of the University of Sciences, Techniques and Technologies of Bamako, who took part in the study, adding that "this could be a very good tool" in logistical and programme terms.

Robert Seder of the US National Institute of Allergy and Infectious Diseases, whose lab helped develop L9LS, said researchers would focus on groups other than infants in the pivotal trials they hope to start in 2028; experts cite pregnant women and children discharged from hospital after malaria among them.

Malaria killed about 610,000 people in 2024, most of them children under five in sub-Saharan Africa, according to the same source.

Related stories